Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Baxter Pays $150 Mil. For Somatogen Recombinant Hemoglobin Technology

Executive Summary

Baxter will pay about $150 mil. for a chance to apply Somatogen's recombinant hemoglobin technology to its blood substitute program.

You may also be interested in...

VitaResc Acquisition Of Apex To Fund Septic Shock Treatment Phase III Study

The acquisition of Apex Bioscience by Munich-based start-up VitaResc Biotech AG will provide for the financing of a Phase III program in nitric oxide-induced shock with Apex' lead product, pyridoxalated hemoglobin polyoxyethylene.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts